Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841403 | 0.90 | MAPT (0.51) | SMN1; SMN2MAPTALDH1A1TP53NPSR1 | |
| SCHEMBL5842831 | 0.87 | MAPT (0.65) | SMN1; SMN2MAPTALDH1A1TP53USP2 | |
| SCHEMBL5842706 | 0.86 | ALDH1A1 (0.53) | SMN1; SMN2MAPTALDH1A1TP53USP2 | |
| SCHEMBL5842938 | 0.83 | ALDH1A1 (0.51) | SMN1; SMN2MAPTALDH1A1TP53USP2 | |
| SCHEMBL5842942 | 0.83 | MAPT (0.53) | SMN1; SMN2MAPTALDH1A1TP53USP2 | |
| SCHEMBL5841298 | 0.82 | ALOX15 (0.53) | SMN1; SMN2MAPTALDH1A1TP53NPSR1 | |
| SCHEMBL5843005 | 0.82 | ALDH1A1 (0.49) | SMN1; SMN2MAPTALDH1A1TP53USP2 | |
| SCHEMBL5843928 | 0.82 | ALDH1A1 (0.67) | MAPTALDH1A1TP53USP2GAA | |
| SCHEMBL5844459 | 0.82 | TP53 (0.63) | SMN1; SMN2ALDH1A1TP53USP2GAA | |
| SCHEMBL5843000 | 0.81 | MAPT (0.49) | SMN1; SMN2MAPTALDH1A1TP53USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | claimed |
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | SMN1; SMN2 3678/4885MAPT 4395/4885ALDH1A1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.